|
1
|
Sun K, Zhang B, Lei S, Zheng R, Liang X,
Li L, Feng X, Zhang S, Zeng H, Yao Y, et al: Incidence, mortality,
and disability-adjusted life years of female breast cancer in
China, 2022. Chin Med J (Engl). 137:2429–2436. 2024. View Article : Google Scholar
|
|
2
|
Bizuayehu HM, Ahmed KY, Kibret GD, Dadi
AF, Belachew SA, Bagade T, Tegegne TK, Venchiarutti RL, Kibret KT,
Hailegebireal AH, et al: Global disparities of cancer and its
projected burden in 2050. JAMA Netw Open. 7:e24431982024.
View Article : Google Scholar
|
|
3
|
Huang S, Yang J, Shen N, Xu Q and Zhao Q:
Artificial intelligence in lung cancer diagnosis and prognosis:
Current application and future perspective. Semin Cancer Biol.
89:30–37. 2023. View Article : Google Scholar
|
|
4
|
Rajaram R, Huang Q, Li RZ, Chandran U,
Zhang Y, Amos TB, Wright GWJ, Ferko NC and Kalsekar I:
Recurrence-free survival in patients with surgically resected
non-small cell lung cancer: A systematic literature review and
meta-analysis. Chest. 165:1260–1270. 2024. View Article : Google Scholar
|
|
5
|
Luo H, Wei W, Ye Z, Zheng J and Xu RH:
Liquid biopsy of methylation biomarkers in cell-free DNA. Trends
Mol Med. 27:482–500. 2021. View Article : Google Scholar
|
|
6
|
Zhang L and Li J: Unlocking the secrets:
The power of methylation-based cfDNA detection of tissue damage in
organ systems. Clin Epigenetics. 15:1682023. View Article : Google Scholar
|
|
7
|
González-Masiá JA, García-Olmo D and
García-Olmo DC: Circulating nucleic acids in plasma and serum
(CNAPS): Applications in oncology. Onco Targets Ther. 6:819–832.
2013.
|
|
8
|
Zhou Q, Kang G, Jiang P, Qiao R, Lam WKJ,
Yu SCY, Ma ML, Ji L, Cheng SH, Gai W, et al: Epigenetic analysis of
cell-free DNA by fragmentomic profiling. Proc Natl Acad Sci USA.
119:e22098521192022. View Article : Google Scholar
|
|
9
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar
|
|
10
|
Chinese Thoracic Society, . Chinese expert
consensus on diagnosis of early lung cancer (2023 Edition)].
Zhonghua Jie He He Hu Xi Za Zhi. 46:1–18. 2023.(In Chinese).
|
|
11
|
Ding SC and Lo YMD: Cell-Free DNA
fragmentomics in liquid biopsy. Diagnostics (Basel). 12:9782022.
View Article : Google Scholar
|
|
12
|
Han DSC and Lo YMD: The nexus of cfDNA and
nuclease biology. Trends Genet. 37:758–770. 2021. View Article : Google Scholar
|
|
13
|
Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K,
Wang Y, Ding R, Gao L, Ma W, et al: Efficient detection and
post-surgical monitoring of colon cancer with a multi-marker DNA
methylation liquid biopsy. Proc Natl Acad Sci USA.
118:e20174211182021. View Article : Google Scholar
|
|
14
|
Jelski W and Mroczko B: Molecular and
circulating biomarkers of gastric cancer. Int J Mol Sci.
23:75882022. View Article : Google Scholar
|
|
15
|
Wang S, Meng F, Li M, Bao H, Chen X, Zhu
M, Liu R, Xu X, Yang S, Wu X, et al: Multidimensional cell-free DNA
fragmentomic assay for detection of early-stage lung cancer. Am J
Respir Crit Care Med. 207:1203–1213. 2023. View Article : Google Scholar
|
|
16
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View Article : Google Scholar
|
|
17
|
Zeng C, Stroup EK, Zhang Z, Chiu BC and
Zhang W: Towards precision medicine: Advances in
5-hydroxymethylcytosine cancer biomarker discovery in liquid
biopsy. Cancer Commun (Lond). 39:122019.
|
|
18
|
Terasawa H, Kinugasa H, Nouso K, Yamamoto
S, Hirai M, Tanaka T, Takaki A and Okada H: Circulating tumor DNA
dynamics analysis in a xenograft mouse model with esophageal
squamous cell carcinoma. World J Gastroenterol. 27:7134–7143. 2021.
View Article : Google Scholar
|
|
19
|
Heitzer E, Ulz P and Geigl JB: Circulating
tumor DNA as a liquid biopsy for cancer. Clin Chem. 61:112–123.
2015. View Article : Google Scholar
|
|
20
|
Francis G and Stein S: Circulating
cell-free tumour DNA in the management of cancer. Int J Mol Sci.
16:14122–14142. 2015. View Article : Google Scholar
|
|
21
|
Phallen J, Sausen M, Adleff V, Leal A,
Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et
al: Direct detection of early-stage cancers using circulating tumor
DNA. Sci Transl Med. 9:eaan24152017. View Article : Google Scholar
|
|
22
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra2242014. View Article : Google Scholar
|
|
23
|
Leger A, Brettell I, Monahan J, Barton C,
Wolf N, Kusminski N, Herder C, Aadepu N, Becker C, Gierten J, et
al: Genomic variations and epigenomic landscape of the Medaka
inbred kiyosu-karlsruhe (MIKK) panel. Genome Biol. 23:582022.
View Article : Google Scholar
|
|
24
|
Qi J, Hong B, Wang S, Wang J, Fang J, Sun
R, Nie J and Wang H: Plasma cell-free DNA methylome-based liquid
biopsy for accurate gastric cancer detection. Cancer Sci.
115:3426–3438. 2024. View Article : Google Scholar
|
|
25
|
Jain S, Maque J, Galoosian A, Osuna-Garcia
A and May FP: Optimal strategies for colorectal cancer screening.
Curr Treat Options Oncol. 23:474–493. 2022. View Article : Google Scholar
|
|
26
|
Ma MJ, Wang W and Jiang CY: Progress of
circulating tumor DNA in diagnosis and prognosis of pancreatic
cancer. Zhonghua Wai Ke Za Zhi. 59:1036–1040. 2021.(In
Chinese).
|
|
27
|
Xi Y, Bai Z, Gao S, Zhang Z, Zhang H, Qu
L, Xu B, Wang W, Shan G, Cui W, et al: Genomic profiling of
NGS-based ctDNA from Chinese non-small cell lung cancer patients. J
Cancer Res Clin Oncol. 149:8573–8580. 2023. View Article : Google Scholar
|
|
28
|
Byrska-Bishop M, Evani US, Zhao X, Basile
AO, Abel HJ, Regier AA, Corvelo A, Clarke WE, Musunuri R,
Nagulapalli K, et al: High-coverage whole-genome sequencing of the
expanded 1000 Genomes Project cohort including 602 trios. Cell.
185:3426–3440.e19. 2022. View Article : Google Scholar
|
|
29
|
Zhang L, Li D, Gao L, Zhang D, Fu Q, Sun
H, Tan S, Huang H, Zheng T, Tian T, et al: Pan-cancer analysis of
genome-wide methylation profiling discover type-specific markers
targeting circulating free DNA for the detection of colorectal
cancer. Clin Transl Med. 13:e13702023. View Article : Google Scholar
|
|
30
|
Chen Y and Ma S, Lin C, Zhu Z, Bai J, Yin
Z, Sun Y, Mao F, Xue L and Ma S: Integrative analysis of DNA
methylomes reveals novel cell-free biomarkers in lung
adenocarcinoma. Front Genet. 14:11757842023. View Article : Google Scholar
|
|
31
|
Barets D, Appay R, Heinisch M, Battistella
M, Bouvier C, Chotard G, Le Loarer F, Macagno N, Perbet R,
Pissaloux D, et al: Specific and sensitive diagnosis of BCOR-ITD in
various cancers by digital PCR. Front Oncol. 11:6455122021.
View Article : Google Scholar
|
|
32
|
Cardoso GC, Ganzella FAO, Miniskiskosky G,
da Cunha RS and Ramos EAS: Digital methylation-specific PCR: New
applications for liquid biopsy. Biomol Concepts. 15:2024.
View Article : Google Scholar
|
|
33
|
Albrecht C, Bashtrykov P and Jeltsch A:
Amplicon-based bisulfite conversion-NGS DNA methylation analysis
protocol. Methods Mol Biol. 2842:405–418. 2024. View Article : Google Scholar
|
|
34
|
Postel M, Roosen A, Laurent-Puig P, Taly V
and Wang-Renault SF: Droplet-based digital PCR and next generation
sequencing for monitoring circulating tumor DNA: A cancer
diagnostic perspective. Expert Rev Mol Diagn. 18:7–17. 2018.
View Article : Google Scholar
|
|
35
|
Tang J, Fang F, Miller DF, Pilrose JM,
Matei D, Huang TH and Nephew KP: Global DNA methylation profiling
technologies and the ovarian cancer methylome. Methods Mol Biol.
1238:653–675. 2015. View Article : Google Scholar
|
|
36
|
Nikanjam M, Kato S and Kurzrock R: Liquid
biopsy: Current technology and clinical applications. J Hematol
Oncol. 15:1312022. View Article : Google Scholar
|
|
37
|
Cabezas-Camarero S, García-Barberán V,
Pérez-Alfayate R, Casado-Fariñas I, Sloane H, Jones FS and
Pérez-Segura P: Detection of IDH1 mutations in plasma using BEAMing
technology in patients with gliomas. Cancers (Basel). 14:28912022.
View Article : Google Scholar
|
|
38
|
Lastraioli E, Antonuzzo L, Fantechi B, Di
Cerbo L, Di Costanzo A, Lavacchi D, Armenio M, Arcangeli A,
Castiglione F, Messerini L and Di Costanzo F: KRAS and NRAS
mutation detection in circulating DNA from patients with metastatic
colorectal cancer using BEAMing assay: Concordance with standard
biopsy and clinical evaluation. Oncol Lett. 21:152021. View Article : Google Scholar
|
|
39
|
Chen Y, Zhao N, Zhang J, Wu X, Huang J, Xu
X, Cai F, Chen S, Xu L, Yan W, et al: Molecular signatures of
invasive and non-invasive pituitary adenomas: A comprehensive
analysis of DNA methylation and gene expression. BMC Med.
23:3732025. View Article : Google Scholar
|
|
40
|
Nakabayashi K, Yamamura M, Haseagawa K and
Hata K: Reduced representation bisulfite sequencing (RRBS). Methods
Mol Biol. 2577:39–51. 2023. View Article : Google Scholar
|
|
41
|
Lin HY, Lee CL, Fran S, Tu RY, Chang YH,
Niu DM, Chang CY, Chiu PC, Chou YY, Hsiao HP, et al: Quantitative
DNA methylation analysis and epigenotype-phenotype correlations in
taiwanese patients with beckwith-wiedemann syndrome. J Pers Med.
11:10662021. View Article : Google Scholar
|
|
42
|
Lin HY, Lee CL, Tu YR, Chang YH, Niu DM,
Chang CY, Chiu PC, Chou YY, Hsiao HP, Tsai MC, et al: Quantitative
DNA methylation analysis and epigenotype-phenotype correlations in
Taiwanese patients with silver-russell syndrome. Int J Med Sci.
21:8–18. 2024. View Article : Google Scholar
|
|
43
|
Wang S, Song J, Yang Y, Zhang Y, Wang H
and Ma J: HIF3A DNA methylation is associated with childhood
obesity and ALT. PLoS One. 10:e01459442015. View Article : Google Scholar
|
|
44
|
De Chiara L, Leiro-Fernandez V,
Rodríguez-Girondo M, Valverde D, Botana-Rial MI and
Fernández-Villar A: Comparison of bisulfite pyrosequencing and
methylation-specific qPCR for methylation assessment. Int J Mol
Sci. 21:92422020. View Article : Google Scholar
|
|
45
|
Lee JS, Kim M, Seong MW, Kim HS, Lee YK
and Kang HJ: Plasma vs. serum in circulating tumor DNA measurement:
Characterization by DNA fragment sizing and digital droplet
polymerase chain reaction. Clin Chem Lab Med. 58:527–532. 2020.
View Article : Google Scholar
|
|
46
|
Huang Z and Liu F: Diagnostic value of
serum carbohydrate antigen 19-9 in pancreatic cancer: A
meta-analysis. Tumour Biol. 35:7459–7465. 2014. View Article : Google Scholar
|
|
47
|
Bauer TM, El-Rayes BF, Li X, Hammad N,
Philip PA, Shields AF, Zalupski MM and Bekaii-Saab T: Carbohydrate
antigen 19-9 is a prognostic and predictive biomarker in patients
with advanced pancreatic cancer who receive gemcitabine-containing
chemotherapy: A pooled analysis of 6 prospective trials. Cancer.
119:285–292. 2013. View Article : Google Scholar
|
|
48
|
Majumder S, Taylor WR, Foote PH, Berger
CK, Wu CW, Mahoney DW, Bamlet WR, Burger KN, Postier N, de la
Fuente J, et al: High detection rates of pancreatic cancer across
stages by plasma assay of novel methylated DNA markers and CA19-9.
Clin Cancer Res. 27:2523–2532. 2021. View Article : Google Scholar
|
|
49
|
Li Y, Fan Z, Meng Y, Yang J, Li P, Liu S,
Pang C, Du L, Wang Y and Zhan H: ZFHX3 methylation in peripheral
blood monocytes as a potential biomarker for pancreatic cancer
detection. Pancreatology. 24:771–778. 2024. View Article : Google Scholar
|
|
50
|
Lobato-Delgado B, Priego-Torres B and
Sanchez-Morillo D: Combining molecular, imaging, and clinical data
analysis for predicting cancer prognosis. Cancers (Basel).
14:32152022. View Article : Google Scholar
|
|
51
|
Zhou X, Cheng Z, Dong M, Liu Q, Yang W,
Liu M, Tian J and Cheng W: Tumor fractions deciphered from
circulating cell-free DNA methylation for cancer early diagnosis.
Nat Commun. 13:76942022. View Article : Google Scholar
|
|
52
|
Chemi F, Pearce SP, Clipson A, Hill SM,
Conway AM, Richardson SA, Kamieniecka K, Caeser R, White DJ, Mohan
S, et al: cfDNA methylome profiling for detection and subtyping of
small cell lung cancers. Nat Cancer. 3:1260–1270. 2022. View Article : Google Scholar
|
|
53
|
Grisolia P, Tufano R, Iannarone C, De
Falco A, Carlino F, Graziano C, Addeo R, Scrima M, Caraglia F,
Ceccarelli A, et al: Differential methylation of circulating free
DNA assessed through cfMeDiP as a new tool for breast cancer
diagnosis and detection of BRCA1/2 mutation. J Transl Med.
22:9382024. View Article : Google Scholar
|
|
54
|
Li Y, Fan Z, Meng Y, Liu S and Zhan H:
Blood-based DNA methylation signatures in cancer: A systematic
review. Biochim Biophys Acta Mol Basis Dis. 1869:1665832023.
View Article : Google Scholar
|
|
55
|
Lau BT, Almeda A, Schauer M, McNamara M,
Bai X, Meng Q, Partha M, Grimes SM, Lee H, Heestand GM and Ji HP:
Single-molecule methylation profiles of cell-free DNA in cancer
with nanopore sequencing. Genome Med. 15:332023. View Article : Google Scholar
|
|
56
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.
|
|
57
|
Qaseem A, Harrod CS, Crandall CJ, Wilt TJ;
Clinical Guidelines Committee of the American College of
Physicians, ; Balk EM, Cooney TG, Cross JT Jr, Fitterman N, Maroto
M, et al: Screening for colorectal cancer in asymptomatic
average-risk adults: A guidance statement from the American college
of physicians (Version 2). Ann Intern Med. 176:1092–1100. 2023.
View Article : Google Scholar
|
|
58
|
US Preventive Services Task Force, .
Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB,
Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, et al: Screening
for prostate cancer: US preventive services task force
recommendation statement. JAMA. 319:1901–1913. 2018. View Article : Google Scholar
|
|
59
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar
|
|
60
|
Nguyen VTC, Nguyen TH, Doan NNT, Pham TMQ,
Nguyen GTH, Nguyen TD, Tran TTT, Vo DL, Phan TH, Jasmine TX, et al:
Multimodal analysis of methylomics and fragmentomics in plasma
cell-free DNA for multi-cancer early detection and localization.
Elife. 12:RP890832023. View Article : Google Scholar
|
|
61
|
Cohen JD, Li L, Wang Y, Thoburn C, Afsari
B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al:
Detection and localization of surgically resectable cancers with a
multi-analyte blood test. Science. 359:926–930. 2018. View Article : Google Scholar
|
|
62
|
Cohen PA, Flowers N, Tong S, Hannan N,
Pertile MD and Hui L: Abnormal plasma DNA profiles in early ovarian
cancer using a non-invasive prenatal testing platform: Implications
for cancer screening. BMC Med. 14:1262016. View Article : Google Scholar
|
|
63
|
Newman AM, Bratman SV, To J, Wynne JF,
Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et
al: An ultrasensitive method for quantitating circulating tumor DNA
with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar
|
|
64
|
Kinde I, Bettegowda C, Wang Y, Wu J,
Agrawal N, Shih IeM, Kurman R, Dao F, Levine DA, Giuntoli R, et al:
Evaluation of DNA from the Papanicolaou test to detect ovarian and
endometrial cancers. Sci Transl Med. 5:167ra42013. View Article : Google Scholar
|
|
65
|
Bianchi DW, Chudova D, Sehnert AJ, Bhatt
S, Murray K, Prosen TL, Garber JE, Wilkins-Haug L, Vora NL, Warsof
S, et al: Noninvasive prenatal testing and incidental detection of
occult maternal malignancies. JAMA. 314:162–169. 2015. View Article : Google Scholar
|
|
66
|
Amant F, Verheecke M, Wlodarska I, Dehaspe
L, Brady P, Brison N, Van Den Bogaert K, Dierickx D, Vandecaveye V,
Tousseyn T, et al: Presymptomatic identification of cancers in
pregnant women during noninvasive prenatal testing. JAMA Oncol.
1:814–819. 2015. View Article : Google Scholar
|
|
67
|
Sun K, Jiang P, Chan KC, Wong J, Cheng YK,
Liang RH, Chan WK, Ma ES, Chan SL, Cheng SH, et al: Plasma DNA
tissue mapping by genome-wide methylation sequencing for
noninvasive prenatal, cancer, and transplantation assessments. Proc
Natl Acad Sci USA. 112:E5503–E5512. 2015. View Article : Google Scholar
|
|
68
|
Gormally E, Vineis P, Matullo G, Veglia F,
Caboux E, Le Roux E, Peluso M, Garte S, Guarrera S, Munnia A, et
al: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and
subsequent cancer occurrence: A prospective study. Cancer Res.
66:6871–6876. 2006. View Article : Google Scholar
|
|
69
|
Mao L, Hruban RH, Boyle JO, Tockman M and
Sidransky D: Detection of oncogene mutations in sputum precedes
diagnosis of lung cancer. Cancer Res. 54:1634–1637. 1994.
|
|
70
|
Zhang S, He S, Zhu X, Wang Y, Xie Q, Song
X, Xu C, Wang W, Xing L, Xia C, et al: DNA methylation profiling to
determine the primary sites of metastatic cancers using
formalin-fixed paraffin-embedded tissues. Nat Commun. 14:56862023.
View Article : Google Scholar
|
|
71
|
Tao Y, Xing S, Zuo S, Bao P, Jin Y, Li Y,
Li M, Wu Y, Chen S, Wang X, et al: Cell-free multi-omics analysis
reveals potential biomarkers in gastrointestinal cancer patients'
blood. Cell Rep Med. 4:1012812023. View Article : Google Scholar
|
|
72
|
Bie F, Wang Z, Li Y, Guo W, Hong Y, Han T,
Lv F, Yang S, Li S, Li X, et al: Multimodal analysis of cell-free
DNA whole-methylome sequencing for cancer detection and
localization. Nat Commun. 14:60422023. View Article : Google Scholar
|
|
73
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar
|
|
74
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540. 2012.
View Article : Google Scholar
|
|
75
|
Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G,
Wang W, Sheng H, Pu H, Mo H, et al: Circulating tumor DNA
methylation profiles enable early diagnosis, prognosis prediction,
and screening for colorectal cancer. Sci Transl Med.
12:eaax75332020. View Article : Google Scholar
|
|
76
|
Ma Y, Li J, Zhao X, Ji C, Hu W, Ma Y, Qu
F, Sun Y and Zhang X: Multi-omics cluster defines the subtypes of
CRC with distinct prognosis and tumor microenvironment. Eur J Med
Res. 29:2072024. View Article : Google Scholar
|
|
77
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar
|
|
78
|
Gay CM, Stewart CA, Park EM, Diao L,
Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, et al:
Patterns of transcription factor programs and immune pathway
activation define four major subtypes of SCLC with distinct
therapeutic vulnerabilities. Cancer Cell. 39:346–360.e7. 2021.
View Article : Google Scholar
|
|
79
|
Zhang S and Cheng T: Prognostic and
clinicopathological value of systemic inflammation response index
(SIRI) in patients with breast cancer: A meta-analysis. Ann Med.
56:23377292024. View Article : Google Scholar
|
|
80
|
Gensheimer MF, Gee H, Shirato H, Taguchi
H, Snyder JM, Chin AL, Vitzthum LK, Maxim PG, Wakelee HA, Neal J,
et al: Individualized stereotactic ablative radiotherapy for lung
tumors: The iSABR phase 2 nonrandomized controlled trial. JAMA
Oncol. 9:1525–1534. 2023. View Article : Google Scholar
|
|
81
|
Lv T, Meng Y, Liu Y, Han Y, Xin H, Peng X
and Huang J: RNA nanotechnology: A new chapter in targeted therapy.
Colloids Surf B Biointerfaces. 230:1135332023. View Article : Google Scholar
|
|
82
|
Xia NM, Zhao YT, Yang QK, Dong LL, Zhang
W, Huang Y and Zang WQ: Evaluation of diagnostic performance of
plasma cfDNA methylation combined detection in diagnosis of
hepatocellular carcinoma. DOI:
10.3969/j.issn.1004-437X.2024.11.001. Henan Medical Research.
33:1921–1925. 2024.
|
|
83
|
Heeke S, Gay CM, Estecio MR, Tran H,
Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, et al: Tumor-
and circulating-free DNA methylation identifies clinically relevant
small cell lung cancer subtypes. Cancer Cell. 42:225–237.e5. 2024.
View Article : Google Scholar
|
|
84
|
Dziechciowska I, Dąbrowska M, Mizielska A,
Pyra N, Lisiak N, Kopczyński P, Jankowska-Wajda M and Rubiś B:
miRNA expression profiling in human breast cancer diagnostics and
therapy. Curr Issues Mol Biol. 45:9500–9525. 2023. View Article : Google Scholar
|
|
85
|
Gevensleben H, Garcia-Murillas I, Graeser
MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A and Turner
NC: Noninvasive detection of HER2 amplification with plasma DNA
digital PCR. Clin Cancer Res. 19:3276–3284. 2013. View Article : Google Scholar
|
|
86
|
Gifford G, Paul J, Vasey PA, Kaye SB and
Brown R: The acquisition of hMLH1 methylation in plasma DNA after
chemotherapy predicts poor survival for ovarian cancer patients.
Clin Cancer Res. 10:4420–4426. 2004. View Article : Google Scholar
|
|
87
|
Rusan M, Andersen RF, Jakobsen A and
Steffensen KD: Circulating HOXA9-methylated tumour DNA: A novel
biomarker of response to poly (ADP-ribose) polymerase inhibition in
BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 125:121–129.
2020. View Article : Google Scholar
|
|
88
|
Wang H, Zhang B, Chen D, Xia W, Zhang J,
Wang F, Xu J, Zhang Y, Zhang M, Zhang L, et al: Real-time
monitoring efficiency and toxicity of chemotherapy in patients with
advanced lung cancer. Clin Epigenetics. 7:1192015. View Article : Google Scholar
|
|
89
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View Article : Google Scholar
|
|
90
|
Ruggieri L, Moretti A, Berardi R, Cona MS,
Dalu D, Villa C, Chizzoniti D, Piva S, Gambaro A and La Verde N:
Host-related factors in the interplay among inflammation, immunity
and dormancy in breast cancer recurrence and prognosis: An overview
for clinicians. Int J Mol Sci. 24:49742023. View Article : Google Scholar
|
|
91
|
Garcia-Murillas I, Schiavon G, Weigelt B,
Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa
I, et al: Mutation tracking in circulating tumor DNA predicts
relapse in early breast cancer. Sci Transl Med. 7:302ra1332015.
View Article : Google Scholar
|
|
92
|
Cha Y, Kim S and Han SW: Utilizing plasma
circulating tumor DNA sequencing for precision medicine in the
management of solid cancers. Cancer Res Treat. 55:367–384. 2023.
View Article : Google Scholar
|
|
93
|
Wang W, Zhu X, Zhang X, Lei C, Zeng Z, Lan
X, Cui W, Wang F, Xu S, Zhou J, et al: Recurrence risk assessment
for stage III colorectal cancer based on five methylation
biomarkers in plasma cell-free DNA. J Pathol. 259:376–387. 2023.
View Article : Google Scholar
|
|
94
|
Yoo TR, Lee JY, Park H, Cho WK, Jeon S,
Jun HR, Lee SB, Chung IY, Kim HJ, Ko BS, et al: Longitudinal
dynamics of circulating tumor DNA for treatment monitoring in
patients with breast cancer recurrence. Sci Rep. 14:202522024.
View Article : Google Scholar
|
|
95
|
Liu J, Sun X, Qin S, Wang H, DU N, Li Y,
Pang Y, Wang C, Xu C and Ren H: CDH1 promoter methylation
correlates with decreased gene expression and poor prognosis in
patients with breast cancer. Oncol Lett. 11:2635–2643. 2016.
View Article : Google Scholar
|
|
96
|
Zhang H, Gao M, Zhao W and Yu L: The
chromatin architectural regulator SND1 mediates metastasis in
triple-negative breast cancer by promoting CDH1 gene methylation.
Breast Cancer Res. 25:1292023. View Article : Google Scholar
|
|
97
|
Chen S, Petricca J, Ye W, Guan J, Zeng Y,
Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, et al: The cell-free
DNA methylome captures distinctions between localized and
metastatic prostate tumors. Nat Commun. 13:64672022. View Article : Google Scholar
|
|
98
|
Dimitrakopoulou-Strauss A, Pan L and
Sachpekidis C: Long axial field of view (LAFOV) PET-CT:
Implementation in static and dynamic oncological studies. Eur J
Nucl Med Mol Imaging. 50:3354–3362. 2023. View Article : Google Scholar
|
|
99
|
Odintsov I and Sholl LM: Prognostic and
predictive biomarkers in non-small cell lung carcinoma. Pathology.
56:192–204. 2024. View Article : Google Scholar
|
|
100
|
Janke F, Angeles AK, Riediger AL, Bauer S,
Reck M, Stenzinger A, Schneider MA, Muley T, Thomas M,
Christopoulos P and Sültmann H: Longitudinal monitoring of
cell-free DNA methylation in ALK-positive non-small cell lung
cancer patients. Clin Epigenetics. 14:1632022. View Article : Google Scholar
|
|
101
|
Balgkouranidou I, Chimonidou M, Milaki G,
Tsaroucha E, Kakolyris S, Georgoulias V and Lianidou E: SOX17
promoter methylation in plasma circulating tumor DNA of patients
with non-small cell lung cancer. Clin Chem Lab Med. 54:1385–1393.
2016. View Article : Google Scholar
|
|
102
|
Mastoraki S, Balgkouranidou I, Tsaroucha
E, Klinakis A, Georgoulias V and Lianidou E: KMT2C promoter
methylation in plasma-circulating tumor DNA is a prognostic
biomarker in non-small cell lung cancer. Mol Oncol. 15:2412–2422.
2021. View Article : Google Scholar
|
|
103
|
Li S, Li W, Liu B, Krysan K and Dubinett
SM: Noninvasive lung cancer subtype classification using
tumor-derived signatures and cfDNA methylome. Cancer Res Commun.
4:1738–1747. 2024. View Article : Google Scholar
|
|
104
|
García-Ortiz MV, Cano-Ramírez P,
Toledano-Fonseca M, Aranda E and Rodríguez-Ariza A: Diagnosing and
monitoring pancreatic cancer through cell-free DNA methylation:
progress and prospects. Biomark Res. 11:882023. View Article : Google Scholar
|
|
105
|
Ben-Ami R, Wang QL, Zhang J, Supplee JG,
Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M,
et al: Protein biomarkers and alternatively methylated cell-free
DNA detect early stage pancreatic cancer. Gut. 73:639–648.
2024.
|
|
106
|
Henriksen SD, Madsen PH, Larsen AC,
Johansen MB, Pedersen IS, Krarup H and Thorlacius-Ussing O:
Cell-free DNA promoter hypermethylation in plasma as a predictive
marker for survival of patients with pancreatic adenocarcinoma.
Oncotarget. 8:93942–93956. 2017. View Article : Google Scholar
|
|
107
|
Elazezy M, Prieske K, Kluwe L,
Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B,
Pantel K and Joosse SA: BRCA1 promoter hypermethylation on
circulating tumor DNA correlates with improved survival of patients
with ovarian cancer. Mol Oncol. 15:3615–3625. 2021. View Article : Google Scholar
|
|
108
|
Liang L, Zhang Y, Li C, Liao Y, Wang G, Xu
J, Li Y, Yuan G, Sun Y, Zhang R, et al: Plasma cfDNA methylation
markers for the detection and prognosis of ovarian cancer.
EBioMedicine. 83:1042222022. View Article : Google Scholar
|
|
109
|
Peng YL, Yu B, Huang TX, Zhou ZH, Zhang H,
Tang WXF, Xu XX, Zhu DQ, Yang RW, Bao H, et al: Early detection of
renal cell carcinoma: A novel cell-free DNA fragmentomics-based
liquid biopsy assay. ESMO Open. 10:1053232025. View Article : Google Scholar
|
|
110
|
Gonzalgo ML, Eisenberger CF, Lee SM, Trock
BJ, Marshall FF, Hortopan S, Sidransky D and Schoenberg MP:
Prognostic significance of preoperative molecular serum analysis in
renal cancer. Clin Cancer Res. 8:1878–1881. 2002.
|
|
111
|
Wan J, Zhu L, Jiang Z and Cheng K:
Monitoring of plasma cell-free DNA in predicting postoperative
recurrence of clear cell renal cell carcinoma. Urol Int.
91:273–278. 2013. View Article : Google Scholar
|
|
112
|
Yamamoto Y, Uemura M, Nakano K, Hayashi Y,
Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K,
et al: Increased level and fragmentation of plasma circulating
cell-free DNA are diagnostic and prognostic markers for renal cell
carcinoma. Oncotarget. 9:20467–20475. 2018. View Article : Google Scholar
|
|
113
|
Perego RA, Corizzato M, Brambilla P,
Ferrero S, Bianchi C, Fasoli E, Signorini S, Torsello B, Invernizzi
L, Bombelli S, et al: Concentration and microsatellite status of
plasma DNA for monitoring patients with renal carcinoma. Eur J
Cancer. 44:1039–1047. 2008. View Article : Google Scholar
|
|
114
|
de Martino M, Klatte T, Haitel A and
Marberger M: Serum cell-free DNA in renal cell carcinoma: A
diagnostic and prognostic marker. Cancer. 118:82–90. 2012.
View Article : Google Scholar
|
|
115
|
Bos MK, Verhoeff SR, Oosting SF, Menke-van
der Houven van Oordt WC, Boers RG, Boers JB, Gribnau J, Martens
JWM, Sleijfer S, van Herpen CML and Wilting SM: Methylated
cell-free DNA Sequencing (MeD-seq) of LpnPI digested fragments to
identify early progression in metastatic renal cell carcinoma
patients on watchful waiting. Cancers (Basel). 15:13742023.
View Article : Google Scholar
|
|
116
|
Smith CG, Moser T, Mouliere F,
Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K,
Wan JCM, Warren AY, et al: Comprehensive characterization of
cell-free tumor DNA in plasma and urine of patients with renal
tumors. Genome Med. 12:232020. View Article : Google Scholar
|
|
117
|
Noë M, Mathios D, Annapragada AV, Koul S,
Foda ZH, Medina JE, Cristiano S, Cherry C, Bruhm DC, Niknafs N, et
al: DNA methylation and gene expression as determinants of
genome-wide cell-free DNA fragmentation. Nat Commun. 15:66902024.
View Article : Google Scholar
|
|
118
|
Stackpole ML, Zeng W, Li S, Liu CC, Zhou
Y, He S, Yeh A, Wang Z, Sun F, Li Q, et al: Cost-effective
methylome sequencing of cell-free DNA for accurately detecting and
locating cancer. Nat Commun. 13:55662022. View Article : Google Scholar
|
|
119
|
Bestvina CM, Waters D, Morrison L, Emond
B, Lafeuille MH, Hilts A, Mujwara D, Lefebvre P, He A and
Vanderpoel J: Impact of next-generation sequencing vs polymerase
chain reaction testing on payer costs and clinical outcomes
throughout the treatment journeys of patients with metastatic
non-small cell lung cancer. J Manag Care Spec Pharm. 30:1467–1478.
2024.
|
|
120
|
Shen SY, Singhania R, Fehringer G,
Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang
TT, Li T, et al: Sensitive tumour detection and classification
using plasma cell-free DNA methylomes. Nature. 563:579–583. 2018.
View Article : Google Scholar
|
|
121
|
He J, Wang B, Tao J, Liu Q, Peng M, Xiong
S, Li J, Cheng B, Li C, Jiang S, et al: Accurate classification of
pulmonary nodules by a combined model of clinical, imaging, and
cell-free DNA methylation biomarkers: A model development and
external validation study. Lancet Digit Health. 5:e647–e656. 2023.
View Article : Google Scholar
|
|
122
|
Zhao Y, Xiong S, Ren Q, Wang J, Li M, Yang
L, Wu D, Tang K, Pan X, Chen F, et al: Deep learning using
histological images for gene mutation prediction in lung cancer: A
multicentre retrospective study. Lancet Oncol. 26:136–146. 2025.
View Article : Google Scholar
|
